Express Pharma

Pharma M&A focuses on increasing product pipelines in Oct 2012

0 52

M&A activity in the pharma sector in October 2012 was focused on increasing product offerings, as the companies were looking to expand their existing businesses.

In line with the above trend, Pfizer agreed to acquire NextWave Pharmaceuticals, a US-based speciality pharmaceutical company, for approximately $680 million. This acquisition would enable Pfizer to focus on the expansion of established US brand’s business. With this transaction, Pfizer will gain access to NextWave’s Quillivant XR, the first once-daily liquid medication approved in the US for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

M&A (including private equity) trend analysis